Idiopathic pulmonary fibrosis (IPF) is a life-threatening condition, with a median survival of<
3 yrs. The pathophysiology is not fully understood, but chronic injury of alveolar epithelial …

Idiopathic pulmonary fibrosis (IPF) is the most common and most lethal diffuse fibrosing lung
disease, with a mortality rate that exceeds that of many cancers. Recently, there have been …

Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …

Highlights•Idiopathic pulmonary fibrosis (IPF) is a progressive disease with no cure.•A
number of clinical trials of potential treatments have recently been completed.•Pirfenidone …

This is a time of substantial progress in the evaluation and care of patients with idiopathic
pulmonary fibrosis (IPF). In addition to the approval and widespread availability of the first …

Idiopathic pulmonary fibrosis (IPF) is a devastating disease with rare incidence but high
mortality, and the pathogenesis of which is still poorly understood. Available treatment …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing disease with disappointing
survival rate, and uneffective therapeutic progress has been made in the last few years …

Idiopathic pulmonary fibrosis (IPF) is a non-neoplastic pulmonary disease that is
characterized by the formation of scar tissue within the lungs in the absence of any known …

Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease
whose cause and course before diagnosis are unknown, and for which existing treatments …

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with unknown etiological factors
that can progress to other dangerous diseases like lung cancer. Environmental and genetic …